Search

RATIONALE, AIMS, AND OBJECTIVES Long-term exposure to glucocorticoids can cause adverse drug reactions of long latency (ADRLLs), including glucocorticoid-induced diabetes mellitus (GID). Providers can monitor for GID using the glycosylated haemoglobin blood (HbA1C) test. This study examined the utility of decisional support to improve HbA1C-based screening for GID. US veterans were identified as chronic users of oral glucocorticoids (>120 days of oral glucocorticoids in the last 2 years). The primary care providers caring for these patients were the target of the intervention. Providers were randomized to receive automatic HbA1C orders for their patients receiving chronic glucocorticoid or usual care. METHODS This study was a pilot two-arm, group-randomized, controlled trial (n = 12 providers, n = 38 patients). Data collection occurred from 5 May 2013 until 10 January 2014. A pharmacist generated the order for an HbA1C through the electronic medical record. The time between the intervention start date and the date on which an HbA1C order was signed were compared using Cox proportional and hierarchical linear regression. RESULTS The time to sign HbA1C orders (mean 12.0 days for the intervention arm; 104.0 days for control arm) was associated with significant differences favouring the intervention [HR (Hazard Ratio) 50.2, P

Rationale, aims, and objectives Adverse drug reactions (ADRs) are a critical concern: they are costly, both in dollars and in diminishing patients' quality of life. ADRs that occur due to prolonged exposure to a pharmaceutical agent (adverse drug reactions of long latency, ADRLLs) may be easier to prevent than acute ADRs, as ADRLLs inherently require continued medication exposures. This pilot study used glucocorticoid-induced osteoporosis (GIO) as an example ADRLL. The aims were to survey health care providers' current practices in avoiding ADRLLs and the perceived utility of decisional support systems (DSS) to aid them in preventing GIO. Methods We administered an anonymous, cross-sectional survey to health care providers (fellows, doctor assistants, nurse practitioners and attending doctors) focusing on their methods to monitor for and prevent ADRLLs. The questionnaire also gauged usage of electronic medical records (EMRs) and each provider's perceived utility of specific DSS-based approaches to monitoring for GIO. Data were interpreted using descriptive statistics and histograms. Results A majority of the 33 responding providers (84.8%) reported that their primary ADRLL avoidance technique is simply remembering that a patient is on chronic glucocorticoids. The most favourably perceived DSS options included tracking medications on a flow sheet (84.8%) and digital tracking of cumulative glucocorticoid exposure with real-time prompts (83.9%). Conclusions Surveyed providers reported that additional DSS implementation may help in the avoidance of ADRLLs such as GIO. Providers ranked both digital and non-digital DSS favourably, but a computerized approach is appealing in that it may be integrated into extant EMR systems.